Home 
Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.9, p.626–630,2021
Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.9, p.626–630,2021
Journal info
|
||||
Select Journal
Journals
Bratislava Medical Journal 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Bratislava Medical Journal Vol.122, No.9, p.626–630,2021 |
||
| Title: Comparison of standard prophylactic and preemptive therapeutic low molecular weight heparin treatments in hospitalized patients with COVID-19 | ||
| Author: B. Copur, S. Surme, U. Sayili, G. Tuncer, E. Zerdali, M. Yazla, I. Y. Nakir, A. Buyukyazgan, A. R. Kurt-Cinar, H. Balli, Y. Kurekci, F. Pehlivanoglu, G. Sengoz | ||
| Abstract: NTRODUCTION: Anticoagulant treatment approach in patients with COVID-19 is not well studied and not standardized. We aimed to compare the effects of standard prophylactic and pre-emptive therapeutic Low-Molecular-weight Heparin (LMWH) treatment approaches on mortality in patients with COVID-19. PATIENTS AND METHODS: This retrospective and single-centre study includes patients aged ≥ 18 years, who were diagnosed with COVID-19 and treated with LMWH during the hospital stay. Therapeutic dose of LMWH was defined as 1 mg/kg subcutaneously twice daily and prophylactic dose of LMWH was defined as 40 mg subcutaneously once daily. RESULTS: Among the 336 patients diagnosed with COVID-19 pneumonia, 115 patients, who received LMWH were included in the study. The mean age was 58.6 ± 13.3 and 58 (50.4 %) of the patients were male. Sixty-nine (60 %) of the patients were treated with prophylactic and 46 (40 %) therapeutic LMWH.In-hospital mortality was not different between patients treated therapeutic LMWH and prophylactic LMWH by the multivariate regression analysis (OR=2.187, 95% CI 0.484–9.880, p=0.309) and the propensity score modelling (OR=1.586, 95% CI 0.400–6.289, p=0.512.) CONCLUSION: Clinicians should consider the potential risks and benefits of standard prophylactic and pre-emptive therapeutic LMWH. Therefore, anticoagulant therapy should be individualized in patients with COVID-19 (Tab. 3, Ref. 28). |
||
| Keywords: anticoagulant therapy, COVID-19, Low-molecular-weight heparin (LMWH), mortality, outcome | ||
| Published online: 31-Aug-2021 | ||
| Year: 2021, Volume: 122, Issue: 9 | Page From: 626, Page To: 630 | |
| doi:10.4149/BLL_2021_100 |
||
|
|
 download file |
|